Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Accounts Payables (2016 - 2025)

Guided Therapeutics' Accounts Payables history spans 16 years, with the latest figure at $2.4 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 15.38% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 15.38% increase, with the full-year FY2025 number at $2.4 million, up 15.38% from a year prior.
  • Accounts Payables hit $2.4 million in Q4 2025 for Guided Therapeutics, up from $2.4 million in the prior quarter.
  • Over the last five years, Accounts Payables for GTHP hit a ceiling of $2.5 million in Q1 2022 and a floor of $29000.0 in Q1 2023.
  • Historically, Accounts Payables has averaged $1.9 million across 5 years, with a median of $2.2 million in 2023.
  • Biggest five-year swings in Accounts Payables: crashed 98.83% in 2023 and later soared 6534.48% in 2024.
  • Tracing GTHP's Accounts Payables over 5 years: stood at $87000.0 in 2021, then surged by 2412.64% to $2.2 million in 2022, then decreased by 8.92% to $2.0 million in 2023, then rose by 5.17% to $2.1 million in 2024, then increased by 15.38% to $2.4 million in 2025.
  • Business Quant data shows Accounts Payables for GTHP at $2.4 million in Q4 2025, $2.4 million in Q3 2025, and $2.3 million in Q2 2025.